CC 90002

Drug Profile

CC 90002

Alternative Names: Anti-CD47 Antibody - Celgene; Ca ImmRx; CC-90002; INBRX-103

Latest Information Update: 28 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Inhibrx
  • Developer Celgene Corporation
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD47 antigen inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Cancer; Myelodysplastic syndromes

Most Recent Events

  • 01 Apr 2017 Pharmacodynamics data from in vitro and preclinical studies in Cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 01 Feb 2016 Phase-I clinical trials in Acute myeloid leukaemia (Second-line therapy or greater) in USA (IV) (NCT02641002)
  • 01 Feb 2016 Phase-I clinical trials in Myelodysplastic syndromes (Second-line therapy or greater) in USA (IV) (NCT02641002)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top